In another study by Ljuca et al., suPAR, showed a stronger prognostic value for assessing the effectiveness of chemotherapy than carcinoembryonic antigen (CEA) and uPA in FIGO II and III ovarian cancer patients (160). This evidence concerns the gene PLAU and ovarian cancer.